Abstract: Air decontamination products are disclosed comprising an air decontamination formulation in an aerosol canister comprising a 2-piece mechanical breakup (MB) nozzle with swirl chamber and approximately 60 psig or more of a pressurizing gas. The air decontamination formulation comprises approximately 10% to approximately 43% by weight of the formulation of dipropylene glycol. The MB nozzle comprises two stem orifices, each having a diameter ranging from approximately 0.036 inches [0.91 mm] to approximately 0.044 inches [1.12 mm]. The disclosed air decontamination formulations may sanitize or disinfect a volume of air less than or equal to 25 m3 in 0.1 to 5 minutes by providing equal to or greater than a 3 log10 reduction of aerosolized bacteria, including Staphylococcus aureus and Klebsiella pneumoniae, and aerosolized enveloped viruses, including Phi6. A 3 log10 reduction of aerosolized non-enveloped viruses, like MS2, occurs in 10-15 minutes.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: A metal powder-based manufacturing system is provided and comprises: a sealed vessel defining a manufacturing chamber; a metal transformation/conversion unit contained in the manufacturing chamber and configured to heat a metal-based feedstock for transformation/conversion; an inert gas source in gas communication with the manufacturing chamber to supply inert gas therein, the inert gas source being operatively connected to the manufacturing chamber through an inert gas line; and at least one gas purifying unit in gas communication with the manufacturing chamber to purify the inert gas to obtain a purified inert gas having an oxygen partial pressure below about 100 ppb. A process for transforming/converting metal in a purified inert gas atmosphere.

Abstract: A neural radiance field (NeRF) is converted to a mesh useful for rendering objects in computer simulations by converting the NeRF to a mesh using voxels and four-sided polygons (“quads”) by iteratively moving vertices of a voxelized version of the NeRF to make pixel values of the NeRF closer to respective pixel values of the mesh while forcing preservation of the quads.

Abstract: A neural radiance field (NeRF) for rendering an image in response to a text description receiving a text description is generated by using first and second polygonal meshes to establish spatial constraints. Points of the NeRF are scored using the spatial constraints to modify the NeRF, which may then be used, typically after conversion to a mesh, in rendering a computer simulation character or object.

Abstract: A text-to-3D machine learning (ML) model is trained by rendering a pre-existing 3D model along with an associated depth map using plural camera settings and rendering a neural radiance field (NeRF) along with an associated depth map using the plural camera settings used in rendering the 3D model. A composite is established from the depth maps, which is used to train the ML model.

Abstract: A metal powder-based manufacturing system is provided and comprises: a sealed vessel defining a manufacturing chamber; a metal transformation/conversion unit contained in the manufacturing chamber and configured to heat a metal-based feedstock for transformation/conversion; an inert gas source in gas communication with the manufacturing chamber to supply inert gas therein, the inert gas source being operatively connected to the manufacturing chamber through an inert gas line; and at least one gas purifying unit in gas communication with the manufacturing chamber to purify the inert gas to obtain a purified inert gas having an oxygen partial pressure below about 100 ppb. A process for transforming/converting metal in a purified inert gas atmosphere.

Abstract: Air decontamination formulations are disclosed comprising approximately 28% to approximately 38% by weight of the formulation of dipropylene glycol; approximately 0.12% to approximately 0.43% by weight of the formulation of an odor neutralizing cationic surfactant; approximately 28% to approximately 50% by weight of the formulation of an alcohol, preferably ethanol; and approximately 14% to approximately 33% by weight of the formulation of water. The disclosed air decontamination formulations sanitize or disinfect a volume of air less than or equal to 25 m3 in 0.1 to 5 minutes by providing equal to or greater than a 3 log10 reduction of aerosolized bacteria, including Staphylococcus aureus and Klebsiella pneumoniae, and aerosolized enveloped viruses, including Phi6.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: The face recognition and identification system comprises a camcorder configured to capture facial image with and without facial accessories; an image pre-processing unit to normalize the captured facial image thereby create window and apply a Haar like features; a feature extraction unit to extract a set of features from the pre-processed facial image; a classifier to classify the set of features in groups including facial image with and without facial accessories; a control unit comprises an artificial intelligence face acknowledgment model to recognize a face and identify a person with and without facial accessories upon comparing the set of features with an image database stored in a cloud server; and a user interface to show the identified person, wherein the user interface concludes the credibility of the individual's face contingent upon the perceived face certainty level, wherein the higher the certainty level the higher the genuineness of the individual.

Abstract: A metal powder-based manufacturing system is provided and comprises: a sealed vessel defining a manufacturing chamber; a metal transformation/conversion unit contained in the manufacturing chamber and configured to heat a metal-based feedstock for transformation/conversion; an inert gas source in gas communication with the manufacturing chamber to supply inert gas therein, the inert gas source being operatively connected to the manufacturing chamber through an inert gas line; and at least one gas purifying unit in gas communication with the manufacturing chamber to purify the inert gas to obtain a purified inert gas having an oxygen partial pressure below about 100 ppb. A process for transforming/converting metal in a purified inert gas atmosphere.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Authorization for access to an application server and associated communication service can be desirably managed. When a device attempts to access an application server and service, an authorization server generates an encrypted token, comprising device identifier information, and communicates the token to the device. The device communicates the token to the application server. The application server communicates the token to the authorization server. The authorization server determines whether the device is validated to access the application server and service based on the encrypted token, private decryption key, and initialization vector, and based on subscriber-related information. The authorization server does not share the private decryption key or initialization vector with the application server. If validated, the authorization server communicates validation-related information, including a permitted portion of subscriber-related information, to the application server.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.